Is Denali Therapeutics (DNLI) the Most Promising Mid-Cap Healthcare Stock Under $50?
On December 11, Wedbush analyst Laura Chico maintained her bullish stance on Denali Therapeutics (NASDAQ:DNLI).
Denali Therapeutics Inc. (DNLI)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Baker Bros. Advisors Julian Baker And Felix Baker | 3,731,695 | $61,610,284 | 0.36% | |
| 2. | Holocene Advisors Brandon Haley | 3,152,734 | $52,051,638 | +1% | 0.11% |
| 3. | Fisher Asset Management Ken Fisher | 2,589,403 | $42,751,042 | +59% | 0.01% |
| 4. | Casdin Capital Eli Casdin | 1,840,000 | $30,378,400 | +107% | 1.89% |
| 5. | Lynx1 Capital Management Weston Nichols | 1,738,750 | $28,706,762 | +565% | 5.81% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.00 | 275,000 | $4,950,000.00 | 19,462,499 | 2017-12-12 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $16.50 | 35,198 | $580,767.00 | 296,833 | 2026-01-06 | Filing | |
| $16.50 | 17,218 | $284,097.00 | 282,828 | 2026-01-06 | Filing | |
| $13.58 | 2,937 | $39,884.46 | 242,346 | 2025-08-12 | Filing | |
| $14.64 | 806 | $11,799.84 | 216,585 | 2025-08-13 | Filing | |
| $13.58 | 2,937 | $39,884.46 | 217,391 | 2025-08-12 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 13,057,890 | $215,585,764 | 0% | |
| 2. | 12,715,201 | $209,927,968 | 0% | |
| 3. | 12,310,889 | $203,252,777 | 0.17% | |
| 4. | 7,012,974 | $115,784,201 | 0.37% | |
| 5. | 6,263,371 | $103,408,255 | 0% |
News See All
15 Most Promising Mid-Cap Healthcare Stocks Under $50
Traditionally, healthcare stocks have been considered defensive, offering strong immunity to business cycles.
H.C. Wainwright Reiterates “Buy” Rating on Denali Therapeutics (DNLI) With $32 PT Following Q3 Results
Fein’s bullish stance followed Denali Therapeutics Inc. (NASDAQ:DNLI)’s Q3 results.
15 Stocks Set to Explode in 2026
While the market figures out whether artificial intelligence is driving the next bubble or the next industrial revolution, a quiet rotation of capital into the next wave of growth leaders outside Big ...
11 Best Future Stocks to Buy Now
Over the past year, investors have poured money into cutting-edge technologies like artificial intelligence and electric cars.
12 Oversold NASDAQ Stocks to Buy Now
On July 14, Max Kettner, chief multi-asset strategist at HSBC, appeared on CNBC to talk about the global markets amid trade tensions.
11 Best Gene Therapy Stocks to Buy According to Analysts
Gene therapy is a medical approach that entails changing or modifying genes to treat or prevent disease.
Jeff Bezos Investments in 2025: 12 Companies Bezos Is Investing In
Since leaving his position as CEO of Amazon in 2021, Jeff Bezos has been quite active.
12 Biotech Stocks with the Biggest Upside Potential
While 2024 was a "challenging" year for biotech stocks, JPMorgan is of the view that some names in the industry may be poised for considerable upside in the coming months.
Hedge Fund Resource Center